Speeding up the development of innovative medicines

Posted on: 10/08/2017

The Innovative Medicines Initiative has launched a EUR 130M call for proposals with focuses on Alzheimer’s disease, big data, vaccines, and more.

The Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients, has launched two new Calls for proposals with topics on Alzheimer‚Äôs disease, big data, vaccines, autoimmune disease, the blood-brain barrier, drug development, and the exploitation of IMI project results. The total budget for the two Calls stands at just over EUR 130 million. Around half of this comes from the European Commission‚Äôs Horizon 2020 programme. The other half comes from EFPIA companies as well as IMI Associated Partners.

Call 11

  • One topic on ‚ÄòExploitation of IMI project results‚Äô

Deadline for submission of proposals: 24 October 2017. Find out more here.

Call 12

  • Topic 1: Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer‚Äôs disease (RADAR-AD)
  • Topic 2: FAIRification of IMI and EFPIA data
  • Topic 3: Development of sensitive and validated clinical endpoints in primary Sj√∂gren‚Äôs Syndrome (pSS)
  • Topic 4: European Health Data Network (EHDN)
  • Topic 5: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
  • Topic 6: Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases
  • Topic 7: European Screening Centre: unique library for attractive biology (ESCulab)

Deadline for submission of proposals: 24 October 2017. Find out more here.

Share this article


Connect with Innovate UK Business Connect

Join Innovate UK Business Connect's mailing list to receive updates on funding opportunities, events and to access Innovate UK Business Connect's deep expertise. Please check your email to confirm your subscription and select your area(s) of interest.